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Background. The development of hydroxyethyl starches (HES) with low impact on blood
coagulation but higher volume effect compared with the currently used HES solutions is of clinical
interest. We hypothesized that high molecular weight, low-substituted HES might possess these
properties.
Methods. Thirty pigs were infused with three different HES solutions (20 ml kg1) with
the same degree of molar substitution (0.42) but different molecular weights (130, 500 and
900 kDa). Serial blood samples were taken over 24 h and blood coagulation was assessed by
Thromboelastograph analysis and analysis of plasma coagulation. In addition, plasma concen-
tration and in vivo molecular weight were determined and pharmacokinetic data were computed
based on a two-compartment model.
Results. Thromboelastograph analysis and plasma coagulation tests did not reveal a more
pronounced alteration of blood coagulation with HES 500 and HES 900 compared with HES
130. In contrast, HES 500 and HES 900 had a greater area under the plasma concentration–time
curve [1542 (142) g min litre1, P<0.001, 1701 (321) g min litre1, P<0.001] than HES 130 [1156
(223) g min litre1] and alpha half life (t½a ) was longer for HES 500 [53.8 (8.6) min, P<0.01] and HES
900 [57.1 (12.3) min, P<0.01] than for HES 130 [39.9 (10.7) min]. Beta half life (t½b ), however, was
similar for all three types of HES [from 332 (100) to 381 (63) min].
Conclusions. In low-substituted HES, molecular weight is not a key factor in compromising
blood coagulation. The longer initial intravascular persistence of high molecular weight low-
substituted HES might result in a longer lasting volume effect.
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Hydroxyethyl starches (HES) are widely used plasma sub-
stitutes.1 2 The clinical use of HES is limited by the effect on
blood coagulation, associated with a reduction in circulat-
ing concentrations of factor VIII and von Willebrand factor
(vWF) in a greater proportion than expected by simple
plasma dilution.3 4 Direct inhibition of platelet function
through binding of HES to the platelet surface may also
contribute to the compromising effects of HES on blood
coagulation.5
HES is a modified branched natural polymer of amylo-
pectin.1 Besides its molecular weight, HES is characterized
by its degree of hydroxyethylation, which is quantified by
the molar substitution ratio. The molar substitution ratio is
defined as the average number of hydroxyethyl groups per
glucose residue present in the HES molecule.1 Studies com-
paring high molecular weight vs low or medium molecular
weight HES show a greater effect on blood coagulation of
high molecular weight HES.6 7 Thus, low and medium
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molecular, low-substituted HES preparations such as HES
130/0.4 (molecular weight 130 kDa, molar substitution 0.4)
and HES 200/0.5 are preferentially used in clinical practice.
The disadvantage of low or medium molecular HES
preparations is shorter intravascular persistence, these
products being more rapidly eliminated than high molecular
weight HES.3
Molecular weight has been considered a key factor in
determining blood coagulation effects of HES.1 Neverthe-
less, the isolated effect of molecular weight on blood
coagulation has not been systematically examined. To date,
a reduction in molecular weight has always been associated
with a reduction in molar substitution (from 450/0.7 to
200/0.5 to 130/0.4). In this study we therefore tested whether
HES molecules with different molecular weight (130–
900 kDa) but identical molar substitution (0.42) would affect
blood coagulation differently. In addition, the intravascular
retention of these HES molecules was assessed.
Materials and methods
The protocol was approved by the Veterinary Office of the
Canton de Vaud, Switzerland. Pigs were handled according
to the guidelines of the Swiss Federal Veterinary Office.
Animal preparation
On arrival at the laboratory, pigs weighing 38 (5) kg received
intramuscular premedication with xylazine 2 mg kg1,
ketamine 20 mg kg1 and atropine 1 mg. Once sedated,
anaesthesia was induced by administration of halothane
3% by mask, followed by tracheal intubation. Controlled
ventilation was started with tidal volumes of 10 ml kg1
and a ventilatory rate of 15 min1 (Ventilator Draeger Sulla
909 V; Dra¨ger, Luebeck, Germany). Anaesthesia was main-
tained with halothane 0.8–1.5% in oxygen and the internal
jugular vein was catheterized. After infusion of HES and
blood sampling via the internal jugular catheter during the
initial 4 h after dosing, the catheter was removed, anaesthe-
sia was terminated and the pig was subsequently transported
back to the animal farm. The next morning, the pigs
were brought back to the laboratory. Premedication and
anaesthesia were administrated as described, and a catheter
was placed into the contralateral internal jugular vein.
After the final blood sample had been obtained, the
animals were killed by an i.v. injection of pentobarbital
150 mg kg1.
HES characterization
HES solutions with different molecular weights but identical
molar substitution were investigated. In order to ensure full
identity of molar substitution and hydroxyethylation pattern,
all three test solutions were manufactured using the same
preparation. Thin-boiling waxy maize starch was suspended
in water, activated by means of sodium hydroxide, and
allowed to react with ethylene oxide for 2 h at 40C. The
amounts of waxy maize starch and ethylene oxide were
chosen to yield HES with a molar substitution of 0.42.
This original HES with its unique hydroxyethylation pattern
was thereafter hydrolysed stepwise by means of treatment
with hydrochloric acid to yield final HES solutions with
molecular weights of 889 kDa (HES 900), 518 kDa (HES
500) and 122 kDa (HES 130). These were treated with
activated carbon, purified by ultrafiltration, diluted to a
final concentration of 6% (w/v) in 0.9% saline, added in
volumes of 500 ml to glass bottles and heat-sterilized at
121C for 20 min. For determination and verification of HES
molecular weights, HES sample solutions were analysed in
duplicate by GPC-MALLS (Wyatt Technology, Woldert,
Germany) at a flow rate of 1 ml min1 in phosphate buffer
70 mM, pH 7.0, using serial GPC columns HEMA Bio 40,
100 and 1000 (PSS, Mainz, Germany). Mean average
molecular weight was calculated using Astra software
(Wyatt Technology). The degree of molar substitution of
the HES solutions was determined and verified in duplicate
according to the method described by Hodges et al.8 and
Lee et al.9 Physicochemical parameters are shown in
Table 1.
Experimental protocol
Animals were randomized into three groups of 10 pigs each,
receiving HES 130, HES 500 or HES 900 at 20 ml kg1 body
weight of the respective 6% HES solution (blinded to the
experimental investigators) was infused over 30 min as a
top-load dose. Blood samples were taken before (baseline)
and 5, 20, 40, 60, 120 and 240 min and 24 h after the end of
the HES infusion.
Laboratory measurements
Whole blood measurements
Citrated blood samples at each sampling time were pro-
cessed in the laboratory as follows.
Viscosity. One sample was immediately used for blood
viscosity measurement (Rheostress 1; Thermo Haake,
Karlsruhe, Germany), for linear increasing shear rates
from 1 to 240 s1. Viscosity at shear rates of 1, 4 and
128 s1 were analysed.
Thromboelastograph analysis (TEG; Haemoscope Cor-
poration, Niles, IL, USA). This provides a more compre-
hensive way of monitoring the process of blood coagulation
by testing the kinetics of the whole coagulation process.10 It
has been shown previously that TEG in conjunction with
conventional coagulation assays provides a complementary
Table 1 HES characterization
HES
130/0.42
HES
500/0.42
HES
900/0.42
In vitro molecular weight (kDa) 122 518 889
Molar substitution 0.42 0.42 0.42
Concentration 6% 6% 6%
Viscosity (mPas) at shear rate of 128 s1 1.9 2.6 3.0
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approach suitable for detection of coagulation abnormalities
in the course of haemodilution by colloids.11 The theory of
TEG, including definition of measured parameters, has been
extensively described earlier.12 13
Before TEG, blood samples were incubated for 1 h in a
37C water bath.14 Blood recalcification and TEG measure-
ments were performed according to the manufacturer’s
instructions. The following TEG parameters are reported:
reaction time (r), coagulation time (k), maximal amplitude
(MA), angle (a) and coagulation index (CI).14 15
Plasma measurements
Blood samples were centrifuged at 3000 r.p.m. for 15 min at
4C (Rotanta/RP; Hettich, Baech, Switzerland). Plasma vis-
cosity measurements were performed as described above for
blood viscosity measurements.
Prothrombin time (PT) and activated partial throm-
boplastin time (aPTT) were determined with an automated
coagulation analyser (BCS; Dade Behring, Marburg, Ger-
many) using a PT reagent containing recombinant tissue
factor (Innovin; Dade Behring) and an aPTT reagent con-
taining ellagic acid (Actin FS, Dade Behring), respect-
ively. Functional activity of vWF was determined with a
commercial ristocetin–cofactor assay (vWF RCA; Dade
Behring) using an automated coagulation analyser (BCS,
Dade Behring). Briefly, vWF activity was assessed by the
ability to agglutinate fixed human platelets in the presence of
ristocetin. Agglutination was measured turbidimetrically
using the coagulation analyser. Antigenic vWF concen-
trations were assayed using a commercial ELISA kit
(Asserachrom vWF antigenic; Roche Diagnostics, Rotkreuz,
Switzerland) according to the manufacturer’s instructions.
HES concentration was quantified after extraction from
plasma and hydrolysis to glucose monomers. Briefly, plasma
samples (1 ml) were incubated at 100C for 60 min after
addition of 0.5 ml KOH solution 35% (w/w) (Fluka, Buchs,
Switzerland). HES was precipitated by adding ice-cold
absolute ethanol (Fluka, Buchs, Switzerland) 10 ml to the
supernatant of the reaction mixture and acid hydrolysed in
2 N HCl (Fluka) for 60 min at 100C. Glucose determination
was performed using an enzymatic test kit based on hexo-
kinase/glucose 6-phosphatase (Boehringer Mannheim,
Darmstadt, Germany). For determination of HES molecular
weight, plasma proteins were eliminated by trichloroacetic
acid precipitation [6.4% (w/w) end concentration] and neut-
ralized supernatants were analysed by GPC-MALLS as
described above (see HES characterization).
Pharmacokinetic modelling
Calculations of pharmacokinetic parameters were per-
formed according to a two-compartment pharmacokinetic
model with constant i.v. infusion rate and first-order output,
using actual doses and duration of infusion. WinNonlin,
Version 4.1 (Pharsight, Mountainview, CA, USA) was
used for model-fitting using starting values automatically
generated by the program and iterative reweighting with
1/(predicted). The quality of fit of the two-compartment
model was confirmed by comparison of observed with pre-
dicted plasma concentrations according to the chosen two-
compartment model. This comparison was completed by
searching for absence of any systematic trend across the
whole concentration range in the residual plot analysis.
Statistical analysis
Results are expressed as mean (SD). The two high molecular
weight (500 and 900 kDa) HES solutions were compared
with the low molecular weight (130 kDa) solution using the
JMP 5.1 statistical package (SAS Institute, Cary, NC, USA).
Data (with and without baseline correction) were analysed
using a two-way ANOVA for repeated measures on one way
(time) with Greenhouse–Geisser correction including solu-
tion and time effects. For statistical analysis of the pharma-
cokinetic parameters, unpaired Student’s t-test was used.
Bonferroni correction was used to avoid bias due to multiple
comparisons when appropriate. P<0.05 was considered stat-
istically significant.
Results
There were no significant differences among the three
animal groups in body weight, baseline haemoglobin con-
centration and coagulation parameters.
Coagulation analyses
Plasma coagulation
All three HES solutions showed a significant time effect
towards hypocoagulation for all plasma coagulation para-
meters (PT, aPTT, vWF activity and antigenic vWF con-
centrations), with a maximum effect immediately after
infusion (P<0.004 for all parameters). On the basis of the
baseline-corrected plasma coagulation parameters measured
(PT, aPTT, vWF activity and antigenic vWF concentrations)
there was no significant difference between HES 500 and
HES 900 when compared with HES 130 (Fig. 1A–D).
TEG
The three HES solutions showed a significant time effect
towards hypocoagulation for all TEG parameters after
infusion of the respective solution (P<0.002 for all). The
maximum effect was seen immediately after infusion. HES
500 and HES 900 did not impair blood coagulation more
than HES 130 (Fig. 2A–E). Notably, the difference between
MA in the HES 900 and the HES 130 group (P=0.042)
(Fig. 2C) was not statistically significant, because of
Bonferroni correction.
HES pharmacokinetics
The concentration curve of the HES preparations was
adequately fitted by a two-compartment model, as shown
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by the excellent correlation between observed vs predicted
plasma concentrations (R2=0.997) (Fig. 3A). This was con-
firmed by the absence of any systematic trend across the
whole concentration range in the residual plot analysis
(Fig. 3B). In accordance with these results, the two-
compartment model was usually chosen for modelling of
HES pharmacokinetics.16
HES concentration was significantly higher for HES 500
(P=0.013) and HES 900 (P=0.014) than for HES 130
(Fig. 4A). Also, in vivo plasma HES molecular weight
was higher for HES 500 (P<0.001) and HES 900
(P<0.001) than for HES 130 (Fig. 4B).
The area under the plasma concentration–time curve was
greater in the HES 500 group (P<0.001) and the HES 900
group (P<0.001) compared with the HES 130 group. Initial
half-life t½a (HES 500, P=0.006; HES 900, P=0.006) was
significantly higher for HES 500 and HES 900 compared
with HES 130. In contrast, terminal half-life t½b did not differ
significantly between groups (Table 2).
Viscosity
Blood and plasma viscosity measurements showed for all
three solutions and at any of the three shear rates analysed
(1, 4 and 128 s1) a significant effect over time (P<0.05 for
all). However, there were no significant differences in the
HES 500 and HES 900 groups compared with the HES 130
group (Fig. 5A–F).
Discussion
This study indicates that low-substituted high molecular
weight HES (HES 500/0.4, HES 900/0.4) does not com-
promise blood coagulation to a greater extent than low-
substituted low molecular HES (130/0.4). In contrast,
low-substituted high molecular HES results in higher plasma
concentration and a longer intravascular persistence without
elevated plasma concentration at 24 h.
This is a surprising finding since a high molecular
weight has generally been considered a significant factor
in determining the effect of a given HES solution on
blood coagulation, in that the higher the molecular weight
the more the blood coagulation is expected to be comprom-
ised.1 6 However, the development of HES has so far been
characterized by a concomitant reduction in molecular
weight and molar substitution, from HES 450/0.7 to HES
200/0.5 to HES 130/0.4. We have now found that, at
low substitution, high molecular weight HES does not
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compromise blood coagulation more than low molecular
weight HES (Figs 1 and 2).
This is particularly remarkable for two reasons. First, the
measured plasma concentrations of HES 500 and HES 900
were higher than the plasma concentration of HES 130
(Fig. 4A); secondly, the in vivo molecular weight of HES
500 and HES 900 was higher than the in vivo molecular
weight of HES 130 (Fig. 4B). This is an important observa-
tion since in vivo molecular weight has been described as
being more important in terms of effect on blood coagulation
than in vitro molecular weight, the molecular weight of the
HES molecules before infusion.17 18 The differentiation
between in vitro and in vivo molecular weight is clearly im-
portant, given the large difference regularly observed18 and
again found in this study (Fig. 4B and Table 1). Nevertheless,
the effect on blood coagulation of low-substituted high
molecular weight HES is not greater than that of low-
substituted low molecular weight HES, indicating that
molecular weight is not a key factor in determining the effect
on blood coagulation.
The higher concentrations over time and the greater area
under the curve (AUC) of the high molecular HES suggest a
longer intravascular persistence of these solutions. The ini-
tial half-life t½a was longer with the high than with the low
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molecular weight HES. The difference in the initial half-life
t½a may be explained by the fact that high molecular weight
HES needs more time to be degraded to a level similar to that
already present with low molecular weight HES from the
beginning. The proximal part of the elimination kinetics may
be important in terms of the effect as a volume replacement
fluid, indicating a potentially higher intravascular volume
effect of high molecular weight HES. In contrast to the
initial half-life t½a , terminal half-life t
½
b did not show any
difference between the groups. This suggests that there is no
increased risk of accumulation after repeated-dose admin-
istration of low-substituted high molecular weight compared
with low-substituted low molecular weight HES.
The porcine model is considered a suitable model for
blood coagulation research.19 It has been used to monitor
coagulation changes under various interventions, such as in
normovolaemic haemodilution, supracoeliac aortic cross-
clamping and haemorrhagic shock.20–22 More importantly,
the changes in coagulation parameters due to HES infusions
measured in our current animal study are similar to those
observed in a previous study in humans.11 In that study, low
and medium molecular weight (70 and 200 kDa) HES were
given to healthy human volunteers at a dose of 15 ml kg1,
which is similar to the dose we used in our pig study
(20 ml kg1). As indicated above, the changes in coagulation
parameters (conventional coagulation tests and throm-
boelastography) over 24 h were strikingly similar in
both human and porcine studies. In addition, it has been
shown by McLoughlin et al. that the response of PT and
aPTT to profound haemodilution is similar in humans and
pigs.20 Porcine coagulation thus seems to react quite
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similarly to HES infusion when compared with the human
coagulation system.
The present study is limited to a 20 ml kg1 top-load dose,
resulting in haemodilution of approximately 20%. Future
studies are necessary to assess whether low-substituted
high molecular weight HES still does not compromise
blood congulation more than low-substituted low molecular
weight HES when higher doses are administered or when
blood loss is compensated by the infusion of such HES
solutions. In addition, redosing studies are necessary to con-
firm that low-substituted high molecular weight HES does
not accumulate during prolonged dosing.
In summary, we have shown that low-substituted high
molecular weight HES (HES 500/0.42 and HES 900/0.42)
does not compromise blood coagulation to a greater extent
than low-substituted low molecular weight HES (130/0.42)
but has longer intravascular persistence. Molecular weight
may not represent a key factor in determining the effects on
blood coagulation of HES.
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Fig 5 Blood (A–C) and plasma (D–F) viscosity measurements at shear rates ( _g) of 1 s1 (A, D), 4 s1 (B, E) and 128 s1 (C, F). Results are mean (SD). Solution
effect of HES 500 vs HES 130 (Psol HES 500) and HES 900 vs HES 130 (Psol HES 900) as determined by two-way ANOVA. BL (arrow) denotes baseline.
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